Alexandra Smith
Physician Assistant · Emory, TXNPI 1871948992
Payments from drug & device makers
Across 824 payments — averaging $90.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$34K
- Teva Pharmaceuticals USA, Inc.$31K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Neurocrine Biosciences, Inc.$2K
- Vanda Pharmaceuticals Inc.$1K
- Alkermes, Inc.$1K
- plus $4K from 13 others
What the payments were for
- Consulting fees$2000%
- Speaking & faculty fees$45,37561%
- Travel & lodging$12,23616%
- Food & beverage$16,59922%
- Education$3490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 146 | $34,087 |
| Teva Pharmaceuticals USA, Inc. | 179 | $30,632 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 81 | $1,806 |
| Neurocrine Biosciences, Inc. | 75 | $1,692 |
| Vanda Pharmaceuticals Inc. | 55 | $1,361 |
| Alkermes, Inc. | 68 | $1,266 |
| AbbVie | 62 | $919 |
| Johnson & Johnson | 32 | $919 |
| Lundbeck LLC | 44 | $715 |
| Sunovion Pharmaceuticals Inc. | 35 | $528 |
| E.r. Squibb & Sons, L.L.C. | 18 | $282 |
| Indivior Inc. | 10 | $194 |
| Axsome Therapeutics, Inc. | 8 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $88 |
| Janssen Scientific Affairs, LLC | 1 | $60 |
| Eisai Inc. | 2 | $28 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Noven Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$31,941
- UZEDY$27,185
- ABILIFY ASIMTUFII$21,059
- LYBALVI$459
- ARISTADA$448
- INVEGA TRINZA$246
- INVEGA SUSTENNA$240
- Austedo XR$200
- INGREZZA$125
- CAPLYTA$120
- ARISTADA INITIO$112
- Fanapt$107
How this compares
$74,760 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 131 | $446,605 |
| IngrezzaValbenazine Tosylate | 42 | $352,296 |
| Invega HafyeraPaliperidone Palmitate | 16 | $331,907 |
| Invega TrinzaPaliperidone Palmitate | 36 | $328,929 |
| Abilify MaintenaAripiprazole | 96 | $259,073 |
| VraylarCariprazine Hcl | 130 | $204,992 |
| RexultiBrexpiprazole | 109 | $202,229 |
| Abilify AsimtufiiAripiprazole | 28 | $164,770 |
| Risperdal ConstaRisperidone Microspheres | 51 | $89,072 |
| UzedyRisperidone | 20 | $61,530 |
| FanaptIloperidone | 24 | $49,812 |
| PerserisRisperidone | 14 | $34,294 |
| Paliperidone ErPaliperidone | 150 | $30,366 |
| Lurasidone Hcl | 95 | $19,628 |
| Aripiprazole | 354 | $17,125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $919 | $864,607218 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti, Abilify Asimtufii | $34,087 | $626,071233 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,692 | $352,29642 claims |
| AbbVieVraylar | $919 | $204,992130 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $30,632 | $61,53020 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,361 | $49,81224 claims |
| Indivior Inc.Perseris | $194 | $34,29414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.
Other physician assistant in Emory
- Cynthia TrickettDallas$1.3M
- Kristine KuceraMelissa$797K
- Selina SantosAustin$543K
- Matthew BrunoMcKinney$538K
- Anthony DerenciusSan Antonio$507K
- Brooke HodnickSouthlake$479K
- Holly GloverArlington$418K
- Kirk GautierAthens$416K
- Jaime RomanPlano$338K
- Michael WhiteDallas$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.